Analyst Ratings For Core Laboratories N.V. (NYSE:CLB)
Today, Core Laboratories N.V. (NYSE:CLB) stock was downgraded by JPMorgan Chase & Co. from Overweight to Neutral.
There are 7 Hold Ratings, 6 Buy Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.
The current consensus rating on Core Laboratories N.V. (NYSE:CLB) is Hold with a consensus target price of $108.50 per share, a potential 48.43% upside.
Some recent analyst ratings include
- 12/11/2018-Core Laboratories N.V. (NYSE:CLB) gets downgraded to Neutral by JPMorgan Chase & Co.
- 11/16/2018-Core Laboratories N.V. (NYSE:CLB) gets upgraded to Buy by Guggenheim with a price target of $120.00
- 10/31/2018-Core Laboratories N.V. (NYSE:CLB) gets upgraded to Buy by ABN Amro
- 10/29/2018-Core Laboratories N.V. (NYSE:CLB) gets upgraded to Buy by Stifel Nicolaus with a price target of $110.00
- 10/29/2018-Core Laboratories N.V. (NYSE:CLB) had its Hold rating reiterated by Piper Jaffray Companies with a $87.00 price target
- On 10/29/2018 Jan Willem Sodderland, Director, bought 200 with an average share price of $85.76 per share and the total transaction amounting to $17,152.00.
- On 8/14/2018 Kevin Daniels, CAO, sold 73 with an average share price of $112.63 per share and the total transaction amounting to $8,221.99.
- On 2/1/2017 Michael Straughen, Director, bought 106 with an average share price of $118.65 per share and the total transaction amounting to $12,576.90.
- On 1/30/2017 Martha Z Carnes, Director, bought 200 with an average share price of $115.20 per share and the total transaction amounting to $23,040.00.
- On 2/2/2016 Jan Willem Sodderland, Director, bought 300 with an average share price of $93.90 per share and the total transaction amounting to $28,170.00.
- On 5/12/2015 Michael C Kearney, Director, sold 1,000 with an average share price of $128.52 per share and the total transaction amounting to $128,520.00.
- On 11/17/2014 Mark F Elvig, VP, sold 1,000 with an average share price of $138.03 per share and the total transaction amounting to $138,030.00.
About Core Laboratories N.V. (NYSE:CLB)
Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. This segment offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. It also provides proprietary and joint industry studies. The Production Enhancement segment includes services and products relating to reservoir well completions, perforations, stimulations, and production. This segment offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories N.V. was founded in 1936 and is based in Amsterdam, the Netherlands.
Recent Trading Activity for Core Laboratories N.V. (NYSE:CLB)
Shares of Core Laboratories N.V. closed the previous trading session at 73,10 −1,88 2,51 % with 72 shares trading hands.
